

205–2737. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on October 25, 2016, based on a complaint filed by Andrea Electronics Corp. of Bohemia, New York (“Andrea”). 81 FR 73418 (Oct. 25, 2016). The complaint alleges violations of section 337 by reason of infringement of certain claims of U.S. Patent No. 6,049,607 (“the ‘607 patent”), U.S. Patent No. 6,363,345 (“the ‘345 patent”), and U.S. Patent No. 6,377,637 (“the ‘637 patent”). The Commission's notice of investigation named the following respondents: Apple Inc. of Cupertino, California (“Apple”); and Samsung Electronics Co., Ltd. of Gyeonggi-do, Republic of Korea, and Samsung Electronics America, Inc. of Ridgefield Park, New Jersey (collectively, “Samsung”). The Office of Unfair Import Investigations (“OUII”) is also a party in this investigation. Samsung was previously terminated from the investigation. All asserted claims of the ‘607 and ‘637 patents were also previously terminated from the investigation.

On October 26, 2017, the ALJ issued her final ID finding no violation of section 337 by Apple for the ‘345 patent. Specifically, the final ID found that Andrea does not have standing to assert the ‘345 patent, the accused products do not infringe the ‘345 patent, and Andrea has not met the domestic industry requirements.

On November 8, 2017, Andrea and OUII each filed timely petitions for review of the final ID. That same day, Apple filed a contingent petition for review of the final ID. On November 16, 2017, the parties each filed a timely response to the petitions for review. On November 27, 2017, the private parties filed their public interest comments pursuant to Commission Rule 210.50.

No public interest comments were received from the public.

Having examined the record of this investigation, including the ALJ's final ID, the petitions for review, and the responses thereto, the Commission has determined to review-in-part the final ID. Specifically, the Commission has determined to review the ID's findings on (1) standing, (2) infringement, (3) invalidity, (4) inequitable conduct, and (5) domestic industry.

The parties are invited to brief their responses to the following question only, with reference to the applicable law and the evidentiary record.

1. Is a determination on whether a licensee is subject to an exclusive license necessary to reach the “all substantial rights” analysis? Are the factors set forth in *Azure Networks, LLC v. CSR PLC*, 771 F.3d 1336 (Fed. Cir. 2014), *judgment vacated on other grounds*, *CSR PLC et.al. v. Azure Networks*, 135 S. Ct. 1846, 2015 W1 582818 (Apr. 20, 2015), relevant to the question of standing raised in this investigation?

The parties are not to brief other issues on review, which are adequately presented in the parties' existing filings. At this time, the Commission is not requesting written submissions on remedy, public interest, or bonding.

**Written Submissions:** Each party's written submission responding to the above questions and any response to the initial submissions should be no more than 20 pages. The written submissions must be filed no later than close of business on Wednesday, January 24, 2018. Reply submissions must be filed no later than the close of business on Wednesday, January 31, 2018. No further submissions on these issues will be permitted unless otherwise ordered by the Commission.

Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to Commission Rule 210.4(f), 19 CFR 210.4(f). Submissions should refer to the investigation number (“Inv. No. 1026”) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, [https://www.usitc.gov/secretary/documents/handbook\\_on\\_filing\\_procedures.pdf](https://www.usitc.gov/secretary/documents/handbook_on_filing_procedures.pdf)). Persons with questions regarding filing should contact the Secretary, (202) 205–2000.

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the

Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this Investigation may be disclosed to and used: (i) By the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. Appendix 3; or (ii) by U.S. government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All non-confidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: January 11, 2018.

**Lisa R. Barton,**

*Secretary to the Commission.*

[FR Doc. 2018–00736 Filed 1–17–18; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–392]

#### Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 19, 2018.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of

manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on October 23, 2017, Chemtos, LLC, 14101 W. Highway 290, Building 2000B, Austin, Texas 78737-9331 applied to be registered as a bulk manufacturer for the following basic classes of controlled substances:

| Controlled substance  | Drug code | Schedule |
|---|-----------|----------|
| 3-Fluoro-N-methylcathinone (3-FMC) .....  | 1233      | I        |
| Cathinone .....   | 1235      | I        |
| Methcathinone .....   | 1237      | I        |
| 4-Fluoro-N-methylcathinone (4-FMC) .....  | 1238      | I        |
| Pentedrone ( $\alpha$ -methylaminovaleophenone) .....   | 1246      | I        |
| Mephedrone (4-Methyl-N-methylcathinone) .....   | 1248      | I        |
| 4-Methyl-N-ethylcathinone (4-MEC) .....   | 1249      | I        |
| Naphyrone .....   | 1258      | I        |
| N-Ethylamphetamine .....  | 1475      | I        |
| N,N-Dimethylamphetamine .....   | 1480      | I        |
| Fenethylamine .....   | 1503      | I        |
| Aminorex .....  | 1585      | I        |
| 4-Methylaminorex (cis isomer) .....   | 1590      | I        |
| Gamma Hydroxybutyric Acid .....   | 2010      | I        |
| Methaqualone .....  | 2565      | I        |
| Mecloqualone .....  | 2572      | I        |
| JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .....   | 6250      | I        |
| SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) .....                          | 7008      | I        |
| ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....      | 7010      | I        |
| 5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone .....   | 7011      | I        |
| AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .....           | 7012      | I        |
| JWH-019 (1-Hexyl-3-(1-naphthyl)indole) .....  | 7019      | I        |
| MDMB-FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .....             | 7020      | I        |
| AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....                       | 7023      | I        |
| THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone .....                                   | 7024      | I        |
| AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .....         | 7031      | I        |
| MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) .....     | 7032      | I        |
| 5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .....                        | 7033      | I        |
| 5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .....    | 7034      | I        |
| ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .....                  | 7035      | I        |
| MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ..... | 7042      | I        |
| APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .....                                      | 7048      | I        |
| 5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) .....                    | 7049      | I        |
| JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthyl) indole) .....  | 7081      | I        |
| SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole) .....                                     | 7104      | I        |
| JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthyl)indole) .....   | 7118      | I        |
| JWH-122 (1-Pentyl-3-(4-methyl-1-naphthyl) indole) .....   | 7122      | I        |
| UR-144 (1-Pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone .....                                 | 7144      | I        |
| JWH-073 (1-Butyl-3-(1-naphthyl)indole) .....  | 7173      | I        |
| JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthyl)indole) .....   | 7200      | I        |
| AM2201 (1-(5-Fluoropentyl)-3-(1-naphthyl) indole) .....   | 7201      | I        |
| JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) .....  | 7203      | I        |
| PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .....  | 7222      | I        |
| 5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .....                                       | 7225      | I        |
| Alpha-ethyltryptamine .....   | 7249      | I        |
| l-bogaine .....   | 7260      | I        |
| CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) .....                                  | 7297      | I        |
| CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) .....                      | 7298      | I        |
| Lysergic acid diethylamide .....  | 7315      | I        |
| 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) .....   | 7348      | I        |
| Marihuana Extract .....   | 7350      | I        |
| Marihuana .....   | 7360      | I        |
| Tetrahydrocannabinols .....   | 7370      | I        |
| Parahexyl .....   | 7374      | I        |
| Mescaline .....   | 7381      | I        |
| 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2) .....   | 7385      | I        |
| 3,4,5-Trimethoxyamphetamine .....   | 7390      | I        |
| 4-Bromo-2,5-dimethoxyamphetamine .....  | 7391      | I        |
| 4-Bromo-2,5-dimethoxyphenethylamine .....   | 7392      | I        |
| 4-Methyl-2,5-dimethoxyamphetamine .....   | 7395      | I        |
| 2,5-Dimethoxyamphetamine .....  | 7396      | I        |

| Controlled substance  | Drug code | Schedule |
|---|-----------|----------|
| JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) .....                          | 7398      | I        |
| 2,5-Dimethoxy-4-ethylamphetamine .....  | 7399      | I        |
| 3,4-Methylenedioxamphetamine .....  | 7400      | I        |
| 5-Methoxy-3,4-methylenedioxamphetamine .....                                      | 7401      | I        |
| N-Hydroxy-3,4-methylenedioxamphetamine .....                                      | 7402      | I        |
| 3,4-Methylenediox-N-ethylamphetamine .....  | 7404      | I        |
| 3,4-Methylenedioxymethamphetamine .....   | 7405      | I        |
| 4-Methoxyamphetamine .....  | 7411      | I        |
| 5-Methoxy-N,N-dimethyltryptamine .....  | 7431      | I        |
| Alpha-methyltryptamine .....  | 7432      | I        |
| Bufotenine .....  | 7433      | I        |
| Diethyltryptamine .....   | 7434      | I        |
| Dimethyltryptamine .....  | 7435      | I        |
| Psilocybin .....  | 7437      | I        |
| Psilocyn .....  | 7438      | I        |
| 5-Methoxy-N,N-diisopropyltryptamine .....   | 7439      | I        |
| N-Ethyl-1-phenylcyclohexylamine .....   | 7455      | I        |
| 1-(1-Phenylcyclohexyl)pyrrolidine .....   | 7458      | I        |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine .....                                       | 7470      | I        |
| 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine .....                                      | 7473      | I        |
| N-Ethyl-3-piperidyl benzilate .....   | 7482      | I        |
| N-Methyl-3-piperidyl benzilate .....  | 7484      | I        |
| N-Benzylpiperazine .....  | 7493      | I        |
| 4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) .....                           | 7498      | I        |
| 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D) .....                          | 7508      | I        |
| 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E) .....                           | 7509      | I        |
| 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) .....                                   | 7517      | I        |
| 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I) .....                            | 7518      | I        |
| 2-(4-Chiara-2,5-dimethoxyphenyl) ethanamine (2C-C) .....                          | 7519      | I        |
| 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N) .....                          | 7521      | I        |
| 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P) .....                      | 7524      | I        |
| 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C-T-4) .....                | 7532      | I        |
| MDPV (3,4-Methylenedioxypyrovalerone) .....                                       | 7535      | I        |
| 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe) .....  | 7536      | I        |
| 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe) ..... | 7537      | I        |
| 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe) .....   | 7538      | I        |
| Methylone (3,4-Methylenediox-N-methylcathinone) .....                             | 7540      | I        |
| Butylone .....  | 7541      | I        |
| Pentylone .....   | 7542      | I        |
| alpha-pyrrolidinopentiophenone ( $\alpha$ -PVP) .....                             | 7545      | I        |
| alpha-pyrrolidinobutiophenone ( $\alpha$ -PBP) .....                              | 7546      | I        |
| AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) .....                        | 7694      | I        |
| Acetyldihydrocodeine .....  | 9051      | I        |
| Benzylmorphine .....  | 9052      | I        |
| Codeine-N-oxide .....   | 9053      | I        |
| Cyprenorphine .....   | 9054      | I        |
| Desomorphine .....  | 9055      | I        |
| Etorphine (except HCl) .....  | 9056      | I        |
| Codeine methylbromide .....   | 9070      | I        |
| Dihydromorphine .....   | 9145      | I        |
| Difenoxin .....   | 9168      | I        |
| Heroin .....  | 9200      | I        |
| Hydromorphenol .....  | 9301      | I        |
| Methyldesorphine .....  | 9302      | I        |
| Methyldihydromorphine .....   | 9304      | I        |
| Morphine methylbromide .....  | 9305      | I        |
| Morphine methylsulfonate .....  | 9306      | I        |
| Morphine-N-oxide .....  | 9307      | I        |
| Myrophine .....   | 9308      | I        |
| Nicocodeine .....   | 9309      | I        |
| Nicomorphine .....  | 9312      | I        |
| Normorphine .....   | 9313      | I        |
| Pholcodine .....  | 9314      | I        |
| Thebacon .....  | 9315      | I        |
| Acetorphine .....   | 9319      | I        |
| Drotebanol .....  | 9335      | I        |
| U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide) .....    | 9547      | I        |
| AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .....      | 9551      | I        |
| Acetylmethadol .....  | 9601      | I        |
| Allylprodine .....  | 9602      | I        |
| Alphacetylmethadol except levo-alphacetylmethadol .....                           | 9603      | I        |
| Alphameprodine .....  | 9604      | I        |
| Alphamethadol .....   | 9605      | I        |
| Benzethidine .....  | 9606      | I        |

| Controlled substance  | Drug code | Schedule |
|---|-----------|----------|
| Betacetylmethadol   | 9607      | I        |
| Betameprodine   | 9608      | I        |
| Betamethadol  | 9609      | I        |
| Betaprodine   | 9611      | I        |
| Clonitazene   | 9612      | I        |
| Dextromoramide  | 9613      | I        |
| Diampromide   | 9615      | I        |
| Diethylthiambutene  | 9616      | I        |
| Dimenoxadol   | 9617      | I        |
| Dimepheptanol   | 9618      | I        |
| Dimethylthiambutene   | 9619      | I        |
| Dioxaphetyl butyrate  | 9621      | I        |
| Dipipanone  | 9622      | I        |
| Ethylmethylthiambutene  | 9623      | I        |
| Etonitazene   | 9624      | I        |
| Etoxidine   | 9625      | I        |
| Furethidine   | 9626      | I        |
| Hydroxypethidine  | 9627      | I        |
| Ketobemidone  | 9628      | I        |
| Levomoramide  | 9629      | I        |
| Levophenacymorphan  | 9631      | I        |
| Morpheridine  | 9632      | I        |
| Noracymethadol  | 9633      | I        |
| Norlevorphanol  | 9634      | I        |
| Normethadone  | 9635      | I        |
| Norpipanone   | 9636      | I        |
| Phenadoxone   | 9637      | I        |
| Phenampromide   | 9638      | I        |
| Phenoperidine   | 9641      | I        |
| Piritramide   | 9642      | I        |
| Proheptazine  | 9643      | I        |
| Propерidine   | 9644      | I        |
| Racemoramide  | 9645      | I        |
| Trimeperidine   | 9646      | I        |
| Phenomorphane   | 9647      | I        |
| Propiram  | 9649      | I        |
| 1-Methyl-4-phenyl-4-propionoxypiperidine  | 9661      | I        |
| 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine  | 9663      | I        |
| Tilidine  | 9750      | I        |
| Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide)                           | 9811      | I        |
| Para-Fluorofentanyl   | 9812      | I        |
| 3-Methylfentanyl  | 9813      | I        |
| Alpha-methylfentanyl  | 9814      | I        |
| Acetyl-alpha-methylfentanyl   | 9815      | I        |
| Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)                           | 9821      | I        |
| Butyryl Fentanyl  | 9822      | I        |
| 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) | 9824      | I        |
| Beta-hydroxyfentanyl  | 9830      | I        |
| Beta-hydroxy-3-methylfentanyl   | 9831      | I        |
| Alpha-methylthiofentanyl  | 9832      | I        |
| 3-Methylthiofentanyl  | 9833      | I        |
| Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide)                | 9834      | I        |
| Thiofentanyl  | 9835      | I        |
| Beta-hydroxythiofentanyl  | 9836      | I        |
| Amphetamine   | 1100      | II       |
| Methamphetamine   | 1105      | II       |
| Lisdexamfetamine  | 1205      | II       |
| Phenmetrazine   | 1631      | II       |
| Methylphenidate   | 1724      | II       |
| Amobarbital   | 2125      | II       |
| Pentobarbital   | 2270      | II       |
| Secobarbital  | 2315      | II       |
| Glutethimide  | 2550      | II       |
| Nabilone  | 7379      | II       |
| 1-Phenylcyclohexylamine   | 7460      | II       |
| Phencyclidine   | 7471      | II       |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP)   | 8333      | II       |
| Phenylacetone   | 8501      | II       |
| 1-Piperidinocyclohexanecarbonitrile   | 8603      | II       |
| Alphaprodine  | 9010      | II       |
| Anileridine   | 9020      | II       |
| Cocaine   | 9041      | II       |
| Codeine   | 9050      | II       |
| Etorphine HCl   | 9059      | II       |

| Controlled substance                              | Drug code | Schedule |
|---|-----------|----------|
| Dihydrocodeine .....                              | 9120      | II       |
| Oxycodone .....                                   | 9143      | II       |
| Hydromorphone .....                               | 9150      | II       |
| Diphenoxylate .....                               | 9170      | II       |
| Ecgonine .....                                    | 9180      | II       |
| Ethylmorphine .....                               | 9190      | II       |
| Hydrocodone .....                                 | 9193      | II       |
| Levomethorphan .....                              | 9210      | II       |
| Levorphanol .....                                 | 9220      | II       |
| Isomethadone .....                                | 9226      | II       |
| Meperidine .....                                  | 9230      | II       |
| Meperidine intermediate-A .....                   | 9232      | II       |
| Meperidine intermediate-B .....                   | 9233      | II       |
| Meperidine intermediate-C .....                   | 9234      | II       |
| Methadone .....                                   | 9250      | II       |
| Methadone intermediate .....                      | 9254      | II       |
| Metopon .....                                     | 9260      | II       |
| Dextropropoxyphene, bulk (non-dosage forms) ..... | 9273      | II       |
| Morphine .....                                    | 9300      | II       |
| Thebaine .....                                    | 9333      | II       |
| Dihydroetorphine .....                            | 9334      | II       |
| Levo-alphaacetylmethadol .....                    | 9648      | II       |
| Oxymorphone .....                                 | 9652      | II       |
| Noroxymorphone .....                              | 9668      | II       |
| Phenazocine .....                                 | 9715      | II       |
| Thiafentanil .....                                | 9729      | II       |
| Piminodine .....                                  | 9730      | II       |
| Racemethorphan .....                              | 9732      | II       |
| Racemorphan .....                                 | 9733      | II       |
| Alfentanil .....                                  | 9737      | II       |
| Remifentanil .....                                | 9739      | II       |
| Sufentanil .....                                  | 9740      | II       |
| Carfentanil .....                                 | 9743      | II       |
| Tapentadol .....                                  | 9780      | II       |
| Bezitramide .....                                 | 9800      | II       |
| Fentanyl .....                                    | 9801      | II       |
| Moramide-intermediate .....                       | 9802      | II       |

The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers.

Dated: January 5, 2018.

**Susan A. Gibson,**

*Deputy Assistant Administrator.*

[FR Doc. 2018-00710 Filed 1-17-18; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-392]

#### Bulk Manufacturer of Controlled Substances Application: Alcami Wisconsin Corporation

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 19, 2018.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement

Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 4, 2017, Alcami Wisconsin Corporation, W130 N10497 Washington Drive, Germantown, Wisconsin 53022 applied to be registered as a bulk manufacturer

of thebaine (9333), a basic class of controlled substance listed in schedule II.

The company states they plan to conduct clinical trials.

Dated: January 5, 2018.

**Susan A. Gibson,**

*Deputy Assistant Administrator.*

[FR Doc. 2018-00709 Filed 1-17-18; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Notice of Proposed Settlement Agreement Under the Oil Pollution Act

On January 9, 2018, a fully-executed proposed Settlement Agreement was received by the Department of Justice, among the United States on behalf of the U.S. Department of the Interior, U.S. Fish and Wildlife Service ("FWS"), the State of Georgia, on behalf of the Georgia Department of Natural Resources ("GDNR"), and Fukunaga Kaiun Co., Ltd., a Japanese company that was the former operator of the Motor Vessel Fortune Epoch in November 2004.